Overbought Stocks
OGN appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
ORGANON & CO (OGN) Stock Price & Overview
NYSE:OGN • US68622V1061
Current stock price
13.29 USD
+0.04 (+0.3%)
At close:
13.26 USD
-0.03 (-0.23%)
After Hours:
The current stock price of OGN is 13.29 USD. Today OGN is up by 0.3%. In the past month the price increased by 108.96%. In the past year, price increased by 38.58%.
OGN Key Statistics
52-Week Range5.69 - 13.39
Current OGN stock price positioned within its 52-week range.
1-Month Range5.82 - 13.39
Current OGN stock price positioned within its 1-month range.
- Market Cap
- 3.46B
- P/E
- 3.63
- Fwd P/E
- 3.80
- EPS (TTM)
- 3.66
- Dividend Yield
- 0.93%
OGN Stock Performance
Today
+0.3%
1 Week
+18.03%
1 Month
+108.96%
3 Months
+55.62%
Longer-term
6 Months +96.89%
1 Year +38.58%
2 Years -37.69%
3 Years -31.46%
5 Years N/A
10 Years N/A
OGN Stock Chart
OGN Stock Screens
OGN currently appears in the following ChartMill screener lists.
OGN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OGN. When comparing the yearly performance of all stocks, OGN is one of the better performing stocks in the market, outperforming 89.16% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
OGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to OGN. OGN scores excellent on profitability, but there are concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
OGN Earnings
On February 12, 2026 OGN reported an EPS of 0.63 and a revenue of 1.51B. The company missed EPS expectations (-14.22% surprise) and missed revenue expectations (-3.09% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$0.63
Revenue Reported1.507B
EPS Surprise -14.22%
Revenue Surprise -3.09%
OGN Forecast & Estimates
16 analysts have analysed OGN and the average price target is 8.84 USD. This implies a price decrease of -33.48% is expected in the next year compared to the current price of 13.29.
For the next year, analysts expect an EPS growth of -4.34% and a revenue growth -0.7% for OGN
Analysts
Analysts48.75
Price Target8.84 (-33.48%)
EPS Next Y-4.34%
Revenue Next Year-0.7%
OGN Index Membership
OGN is currently included in the following stock indexes tracked on ChartMill.
OGN Financial Highlights
Over the last trailing twelve months OGN reported a non-GAAP Earnings per Share(EPS) of 3.66. The EPS decreased by -10.95% compared to the year before.
Income Statements
Revenue(TTM)6.22B
Net Income(TTM)187.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.01% | ||
| ROA | 1.45% | ||
| ROE | 24.87% | ||
| Debt/Equity | 11.47 |
Chartmill High Growth Momentum
EPS Q2Q%-30%
Sales Q2Q%-5.34%
EPS 1Y (TTM)-10.95%
Revenue 1Y (TTM)-2.92%
OGN Ownership
Ownership
Inst Owners77.51%
Shares260.32M
Float259.06M
Ins Owners0.48%
Short Float %7.18%
Short Ratio2.19
OGN Industry Overview
OGN operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
OGN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OGN
Company Profile
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Company Info
IPO: 2021-05-14
ORGANON & CO
30 Hudson Street, Fl 33
Jersey City NEW JERSEY US
CEO: Kevin Ali
Employees: 10000
Phone: 15514306000
ORGANON & CO / OGN FAQ
Can you describe the business of ORGANON & CO?
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
What is the current price of OGN stock?
The current stock price of OGN is 13.29 USD. The price increased by 0.3% in the last trading session.
Does ORGANON & CO pay dividends?
ORGANON & CO (OGN) has a dividend yield of 0.93%. The yearly dividend amount is currently 0.34.
How is the ChartMill rating for ORGANON & CO?
OGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of ORGANON & CO (OGN)?
The PE ratio for ORGANON & CO (OGN) is 3.63. This is based on the reported non-GAAP earnings per share of 3.66 and the current share price of 13.29 USD.
What is the ownership structure of ORGANON & CO (OGN)?
You can find the ownership structure of ORGANON & CO (OGN) on the Ownership tab.
What is the outstanding short interest for ORGANON & CO?
The outstanding short interest for ORGANON & CO (OGN) is 7.18% of its float.